CYP2D6 acts on 25% of all prescription drugs. ^[33] Approximately 4-7% of the population has a slow acting form of this enzyme and 3% a super-fast acting form. About 35% of the population are carriers of a non-functional CYP2D6 allele, which especially elevates the risk of adverse drug events (ADEs) when these individuals are taking multiple drugs.^[5]

Drugs that CYP2D6 metabolizes include selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants (TCA), beta-blockers, opiates, neuroleptics, antiarrhythmics, and a variety of toxic plant substances.

Genelex offers improved detection rates using an extended Cytochrome P450 2D6 DNA mutation panel. This CYP2D6 test identifies 25 variants of the more common alleles (*2,*2A,*3-*12,*14,*15,*17,*19,*20,*21,*29,*30,*35,*36,*41,*56,*109), gene deletions, gene duplications and gene rearrangements in PCR-multiplex format, providing increased sensitivity and quality performance. Copy number and gene re-arrangement determinations may not always be determined. This CYP2D6 Mutation Detection Panel is the most extensive on the market and covers over 93-97% of poor metabolizer phenotypes. Analytical specificity and sensitivity for detection of these mutations are >99%.